AtheroGenics to Present at JPMorgan Healthcare Conference on Wednesday, January 10, 2007
ATLANTA, GA -- January 04, 2007 -- AtheroGenics, Inc., a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, will be presenting a company overview and update at the 25th Annual JPMorgan Healthcare Conference on Wednesday, January 10, 2007, at 10:30 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco, Calif.
A live audio webcast of the presentation will be available on the AtheroGenics Investor Relations Events website at http://www.atherogenics.com. A replay of the presentation will be available on the Company's website approximately twenty-four hours after the presentation and will be archived for thirty days.
About AtheroGenics
AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has two drug development programs currently in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III ARISE clinical trial as an oral therapy for the treatment of atherosclerosis, in collaboration with AstraZeneca. AGI-1096 is a novel, oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. AtheroGenics also has preclinical programs in rheumatoid arthritis and asthma utilizing its proprietary vascular protectant® technology. For more information about AtheroGenics, please visit http://www.atherogenics.com.